Anti-CD79b (clone ch2F2)-SMCC-DM1 ADC

  • 1.00 Dollar US$
  • Published date: November 10, 2017
    • Shirley, New York, United States

Anti-CD79b (clone ch2F2)-SMCC-DM1 ADC is comprised of an anti-CD79B monoclonal antibody (clone ch2F2) conjugated via a SMCC linker to DM1. The DM1 is targeted to certain cancers by immunerecognition and delivered into cancer cells via receptor mediated endocytosis. Within the cell, DM1 binds to tubulins, interrupts microtubule dynamics, and subsequently, induces cell death.
Derived from Maytansinoid,a group of cytotoxins structurally similar to rifamycin, geldanamycin, and ansatrienin. The eponymous natural cytotoxic agent maytansine is a 19-member lactam (ansa
macrolide) structure originally isolated from the Ethiopian shrub Maytenus ovatus. Maytansinoids can bind to tubulin at or near the vinblastine-binding site, which interfere the formation of microtubules and depolymerize already formed microtubules, inducing mitotic arrest in the intoxicated cells."

Result 0 votes
Bella
1 votes

Useful information

  • Avoid scams by acting locally or paying with PayPal
  • Never pay with Western Union, Moneygram or other anonymous payment services
  • Don't buy or sell outside of your country. Don't accept cashier cheques from outside your country
  • This site is never involved in any transaction, and does not handle payments, shipping, guarantee transactions, provide escrow services, or offer "buyer protection" or "seller certification"

Related listings

  • Understanding the Impacts and (Applications) in the Logistics Industry

    Understanding the Impacts and (Applications) in the Logistics Industry

    Drug Development Fremont (California) October 11, 2018 Free

    Overview: There are countless areas where block chain technology could drive improvement in the logistics industry, but none bigger than the truck driver shortage so we can use it as illustration. Areas Covered in the Session: Block chain basics Hist...

  • Japan Regulatory Compliance Requirements for Life Science Products

    Japan Regulatory Compliance Requirements for Life Science Products

    Drug Development Seattle (Washington) September 5, 2018 1495.00 Dollar US$

    Course "Japan Regulatory Compliance Requirements for Life Science Products" has been pre-approved by RAPS as eligible for up to 12 credits towards a participant's RAC recertification upon full completion. Overview: This 2-Day seminar covers the detai...

  • 2nd Annual Inhalation & Respiratory Drug Delivery USA Congress

    2nd Annual Inhalation & Respiratory Drug Delivery USA Congress

    Drug Development San Diego (California) September 3, 2018 Free

    Oxford Global is proud to present the 2nd Annual Inhalation & Respiratory Drug Delivery USA Congress, 18 – 19 March 2019, San Diego, USA. Over 200 delegates representing leading pharmaceutical organisations, biotech companies internationally reno...